Prevention and treatment of the arctic

First, the introduction of influenza A (A) as an acute respiratory infection caused by the influenza A virus poses a major threat to public health. Particularly in densely populated areas, such as schools, office areas, public transport hubs and so forth, the rate of transmission is extremely rapid when it erupts. Knowledge of the prevention and treatment of the arctic is essential for effective disease prevention and control and for the health of individuals and groups. II. Pathological and transmissible (i) pathogens of the A-flow are influenza A virus, which has numerous subtypes and is highly variable in antigens, such as H1N1 and H3N2. The blood condensers (HA) and neurosamate (NA) on the surface of the virus are key determinants of their pathogenicity and transmission, and their high variability makes it difficult for the human immune system to adapt quickly, even if it has been infected or immunized, it can be rendered ineffective by the virus ‘ s mutation, posing great challenges for prevention and control. (ii) Transmission routes of foam: this is the most important mode of transmission of the arctic current. When infected people cough, sneeze and even speak, the foam that carries a large number of influenza A viruses is sprayed, which temporarily hangs in the air, leaving those around them at great risk of infection if they are inhaled. In closed spaces with poor ventilation, such as classrooms and conference rooms, viral foam concentrations accumulate rapidly and the risk of infection increases dramatically. Exposure transmission: Indirect exposure to the surface of a virus contaminated object, such as doorknobs, elevator buttons, shared stationery, etc., is also a common route of infection. When people touch the parts of the mucous membranes, such as mouth, nose, eyes, etc., with their hands contaminated with the virus, the virus enters and starts the infection process. III. Symptoms of the acetal current (i) are typical of high heat: A manicular patients usually have a high temperature of up to 39°C or higher and have a longer fever, typically 3-5 days, with a relatively low temperature variability during the period, and a possibly short reaction. All-body acid pain: muscles, joints, sores, all over the body, especially on the legs and backs, patients often feel extremely tired, their activities are restricted, and it is difficult to walk and lift hands. Headaches: Momentary pain in both sides of the head, severe pain levels, often associated with dizziness and head swelling, severely affect patients ‘ attention and clarity of thinking. Cough: At first, there was mostly dry cough, with no sip or only a small amount of albacium, which, as the disease developed, increased, could turn to scud wet cough, increased cough levels, colour can be yellow or yellow, suggesting a possible secondary bacterial infection. Swallow pain: Visible pain in the throat, aggravated when swallowed, can be accompanied by a dry, itching and, in some cases, a muted voice, which seriously affects feeding and verbal communication. (ii) A small number of patients with complications are moving rapidly, with the potential for a combination of serious diseases such as pneumonia, respiratory failure and heartitis. Symptoms such as respiratory distress (more than 30 breaths per minute), respiratory distress, chest pain, CPR (more than 100 heart beats per minute and a poor heart rate) and fuzzy consciousness indicate a critical condition requiring immediate medical attention. IV. Prevention of A-stream (i) Vaccination type and applicable population: Each year, the World Health Organization (WHO) predicts the prevalence of influenza A virus on the basis of global surveillance, and thus develops and produces the corresponding influenza vaccine. There are currently options for a Trivalent Influenza vaccine and a tetravalent influenza vaccine, which can prevent two sub-types of influenza A and one sub-type of influenza B, and an additional sub-type of influenza B, which can be built upon. It is recommended that more than six months later, especially at-risk groups such as the elderly, children, pregnant women and chronically ill, be vaccinated each year before the onset of the influenza season. Vaccination time and attention: The best vaccination time is September-November of each year to achieve effective immunization protection before the high influenza onset (usually December-February of the following year). After vaccination, 30 minutes of observation at the inoculation point, observation of the presence of adverse reactions such as allergies, avoidance of water contamination within 24 hours of the inoculation, possible minor response such as low heat and mild pain in the injection area within 1-2 days of the inoculation, more self-resorting. (ii) Good personal hygiene practices for routine preventive measures: Hand-washing is the most basic and critical line of defence, using soap or hand-washing fluids, following a seven-step wash-up method, carefully quenching the various parts of the hands for a period of not less than 20 seconds to ensure that the virus that may be contaminated with the hand is completely removed, especially when it comes before dinner, when it comes out and when it comes to public goods. At the same time, the public is taught to avoid touching the eyes, nose and mouth with their hands and to block the virus from entering the portal. Maintaining indoor air flow: regular window ventilation with a minimum of 2 – 3 times a day for more than 30 minutes each, to replace fresh air with contaminated air that may contain viruses. In densely populated locations, such as offices and classrooms, the construction of air-conditioning facilities, the installation of new wind systems or increased air-conditioning ventilation should be strengthened to reduce the risk of virus transmission. The wearing of masks: During the high-prevalence of influenza, access to densely populated, poorly ventilated sites, such as malls, hospitals, public transport, etc., medical masks or N95 masks is essential. The mask is an effective barrier to viral foam, reduces the risk of inhalation, is worn in such a way that the face is attached to it, avoids the gap resulting in the failure of protection, is periodically replaced, usually every 4 – 6 hours, and immediately after contamination or damp. Avoiding exposure to sources of infection: Minimizing access to high-prevalence areas, and, if necessary, providing personal protection and following closely the dynamics of the epidemic. Patients who are far from the symptoms of influenza, such as those with heat, cough and oscillation, maintain a social distance of at least 1 metre to prevent the spread of foam. 5. Treatment of A-stream (i) general treatment rest and isolation: once a patient has been diagnosed with a flow, he/she shall immediately be kept in isolation from his/her family and avoid infection until at least 24 hours after his/her temperature has returned to normal. During the isolation period, adequate sleep is guaranteed, rest helps to restore the body ‘ s immunity and to combat the virus, and it is generally recommended to sleep 8-10 hours per day. Supplementary water and nutrition: Encourage the patient to drink more water, with a daily drinking volume of 1500 – 2000 ml, drink more warm water, salt water or appropriate fruit juice, maintain the internal water balance and prevent dehydration due to high heat and sweat. At the same time, protein-rich, vitamin-rich, ore-rich food, such as eggs, milk, fresh fruit and vegetables, skinny meat, etc., are provided to enhance the body ‘ s nutritional support and help with rehabilitation. (ii) Medicines for the treatment of anti-viral drugs: the most effective anti-influenza virus treatment starts at the earliest possible time within 36 – 48 hours, with the most common drug being Ostawe, with an adult dose of 75 mg per dose, two times per day, for five days in a row; children, based on their age and weight, conform to medical prescriptions, usually with Ostawe particles or capsules for children aged 1 and over, and children with difficulties in swallowing with the option of dry-mixers. In addition, Zanamibe, Paramibe and others are optional drugs that are applicable to patients in different situations. Symptoms: For high heat, temperature above 38.5°C, accelerants such as acetaminophenol or brofen may be selected for use in instructions or medical advice to avoid multiple superhemorrhages to avoid damage to liver and kidney function; coughers may use ammonium bromine, acetyl semiscal amino acid, etc. Accelerants; a person who has an ache may have mitigating symptoms such as watermelon cream and herb corals. In short, the prevention and control of the A-stream requires a concerted effort on the part of society as a whole, with preventive measures at the individual level, prompt and scientific treatment after illness, enhanced monitoring and early warning by the public health sector, and prevention and control of the disease, in order to respond effectively to the A-stream threat and to safeguard public health.